Ambrilia Biopharma Inc.
TSX : AMB

Ambrilia Biopharma Inc.

November 09, 2006 08:00 ET

Ambrilia to Host Third Quarter 2006 Results Conference Call

ATTENTION BUSINESS/FINANCIAL/HEALTH EDITORS

MONTREAL, QUEBEC--(CCNMatthews - Nov. 9, 2006) - Ambrilia Biopharma Inc.(TSX:AMB), a biopharmaceutical company developing innovative therapeutics in the fields of cancer and infectious diseases, announced today that it will be hosting a conference call on Tuesday, November 14 at 10:00 AM ET, to discuss its third quarter 2006 financial results and provide an update on its lead development programs.

Interested parties may access the conference call by way of telephone or webcast. The numbers to access the conference call are 1(800) 733-7571 (toll free) or (416) 915-5785 (local). The webcast will be available at www.ambrilia.com, Investors section, Conference calls and webcasts.

A replay of the call will be available at www.ambrilia.com, Investors section, Conference calls and webcasts, and the numbers to access the replay are (416) 640-1917 (local) and 1(877) 289-8525 (toll free) with access code 21209183.

ABOUT AMBRILIA BIOPHARMA

Ambrilia Biopharma Inc.(TSX:AMB) is a biopharmaceutical company developing innovative and proprietary early- to mid-stage therapeutics in the fields of oncology and infectious diseases. Ambrilia's product portfolio includes an anti-cancer therapeutic peptide (PCK3145), a novel anti-cancer therapy (TVT-Dox), two oncology specialty generics (Octreotide, Goserelin), the first of which is late-stage and value-added, and promising anti-HIV treatments (PPL-100, Integrase Inhibitor Program and other Anti-virals). Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments that could total up to $US 232 million. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site: www.ambrilia.com

Ambrilia's forward-looking statements

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward-looking statements.

Contact Information